mRNA |
tanespimycin:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.1 |
0.008 |
mRNA |
Dasatinib |
CTRPv2 |
pan-cancer |
AAC |
-0.099 |
0.008 |
mRNA |
EHT 1864 |
GDSC1000 |
pan-cancer |
AAC |
0.09 |
0.008 |
mRNA |
clofarabine |
CTRPv2 |
pan-cancer |
AAC |
0.079 |
0.009 |
mRNA |
dexamethasone |
CTRPv2 |
pan-cancer |
AAC |
-0.088 |
0.01 |
mRNA |
UNC0638:navitoclax (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.096 |
0.01 |
mRNA |
CAY10618 |
CTRPv2 |
pan-cancer |
AAC |
0.09 |
0.01 |
mRNA |
FGIN-1-27 |
CTRPv2 |
pan-cancer |
AAC |
-0.19 |
0.01 |
mRNA |
BRD-A71883111 |
CTRPv2 |
pan-cancer |
AAC |
0.095 |
0.01 |
mRNA |
neratinib |
CTRPv2 |
pan-cancer |
AAC |
-0.09 |
0.01 |